Yanan Zhu
Stock Analyst at Wells Fargo
(0.80)
# 3,686
Out of 4,784 analysts
71
Total ratings
22.64%
Success rate
-16.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGLS Regulus Therapeutics | Upgrades: Overweight | $3 → $6 | $1.73 | +246.82% | 1 | Mar 27, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $2 → $1.5 | $0.21 | +628.16% | 2 | Mar 21, 2025 | |
| AUTL Autolus Therapeutics | Maintains: Overweight | $8 → $6 | $1.66 | +261.45% | 3 | Mar 21, 2025 | |
| MGX Metagenomi | Maintains: Overweight | $25 → $20 | $1.48 | +1,251.35% | 2 | Mar 18, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Overweight | $12 → $10 | $3.65 | +173.97% | 2 | Mar 12, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $58 → $50 | $11.58 | +331.78% | 6 | Mar 7, 2025 | |
| FATE Fate Therapeutics | Maintains: Equal-Weight | $5 → $4 | $0.85 | +370.98% | 3 | Mar 6, 2025 | |
| QURE uniQure | Maintains: Equal-Weight | $35 → $30 | $12.47 | +140.58% | 2 | Feb 28, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $60 → $50 | $8.07 | +519.58% | 4 | Feb 28, 2025 | |
| BLUE bluebird bio | Maintains: Equal-Weight | $40 → $5 | $4.08 | +22.55% | 8 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $15 | $0.78 | +1,820.37% | 6 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $7 → $4 | $1.25 | +220.00% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $4 | $1.22 | +227.87% | 4 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $77 | $31.15 | +147.19% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $40 | $17.94 | +122.97% | 2 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $36.99 | +75.72% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $4.30 | +597.67% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $25 | $3.56 | +602.25% | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $31.60 | +58.23% | 3 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.82 | +387.80% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $1.46 | +30,721.92% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $105 | $22.21 | +372.76% | 2 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $10 | $1.93 | +418.13% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $589.15 | -44.67% | 1 | Feb 2, 2021 |
Regulus Therapeutics
Mar 27, 2025
Upgrades: Overweight
Price Target: $3 → $6
Current: $1.73
Upside: +246.82%
Adaptimmune Therapeutics
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $0.21
Upside: +628.16%
Autolus Therapeutics
Mar 21, 2025
Maintains: Overweight
Price Target: $8 → $6
Current: $1.66
Upside: +261.45%
Metagenomi
Mar 18, 2025
Maintains: Overweight
Price Target: $25 → $20
Current: $1.48
Upside: +1,251.35%
Voyager Therapeutics
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $3.65
Upside: +173.97%
Arcturus Therapeutics Holdings
Mar 7, 2025
Maintains: Overweight
Price Target: $58 → $50
Current: $11.58
Upside: +331.78%
Fate Therapeutics
Mar 6, 2025
Maintains: Equal-Weight
Price Target: $5 → $4
Current: $0.85
Upside: +370.98%
uniQure
Feb 28, 2025
Maintains: Equal-Weight
Price Target: $35 → $30
Current: $12.47
Upside: +140.58%
Intellia Therapeutics
Feb 28, 2025
Maintains: Overweight
Price Target: $60 → $50
Current: $8.07
Upside: +519.58%
bluebird bio
Feb 24, 2025
Maintains: Equal-Weight
Price Target: $40 → $5
Current: $4.08
Upside: +22.55%
Dec 12, 2024
Maintains: Overweight
Price Target: $20 → $15
Current: $0.78
Upside: +1,820.37%
Dec 11, 2024
Downgrades: Equal-Weight
Price Target: $7 → $4
Current: $1.25
Upside: +220.00%
Nov 12, 2024
Maintains: Overweight
Price Target: $17 → $4
Current: $1.22
Upside: +227.87%
Nov 7, 2024
Maintains: Overweight
Price Target: $82 → $77
Current: $31.15
Upside: +147.19%
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $17.94
Upside: +122.97%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $36.99
Upside: +75.72%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $4.30
Upside: +597.67%
Mar 1, 2024
Maintains: Overweight
Price Target: $22 → $25
Current: $3.56
Upside: +602.25%
Jan 3, 2024
Reiterates: Overweight
Price Target: $50
Current: $31.60
Upside: +58.23%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.82
Upside: +387.80%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $1.46
Upside: +30,721.92%
Mar 1, 2023
Maintains: Overweight
Price Target: $125 → $105
Current: $22.21
Upside: +372.76%
Jan 4, 2023
Maintains: Overweight
Price Target: $14 → $10
Current: $1.93
Upside: +418.13%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $589.15
Upside: -44.67%